AI assistant
Sending…
Monopar Therapeutics — Director's Dealing 2020
Feb 21, 2020
32883_dirs_2020-02-20_5394c3ba-324a-4a10-8e8a-f88c48e717ed.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2020-01-31
Reporting Person: Tsuchimoto Kim R (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-01-31 | Restricted Stock Units | $0 | A | 4923 | Acquired | Common Stock (4923) | Direct | |
| 2020-01-31 | Stock Options | $14.35 | A | 20455 | Acquired | 2030-01-31 | Common Stock (20455) | Direct |
Footnotes
F1: Restricted stock units vest 25% on January 1, 2021, 25% on January 1, 2022, 25% on January 1, 2023, and 25% on January 1, 2024.
F2: Stock Options vest 6/48ths on the 6-month anniversary of vesting commencement date of January 1, 2020, and 1/48th per month thereafter.